![]() |
JOURNAL TOOLS |
Opzioni di pubblicazione |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Publication history |
Estratti |
Permessi |
Per citare questo articolo |
Share |


I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEW
Panminerva Medica 2021 December;63(4):491-8
DOI: 10.23736/S0031-0808.20.04079-3
Copyright © 2020 EDIZIONI MINERVA MEDICA
lingua: Inglese
Novel insights on lymphoma and lymphomagenesis in primary Sjögren’s Syndrome
Alessia ALUNNO 1, Maria C. LEONE 2, Elena BARTOLONI 1, Roberto GERLI 1, Francesco CARUBBI 3 ✉
1 Unit of Rheumatology, University of Perugia, Perugia, Italy; 2 Unit of Rheumatology, S. Maria Hospital, Terni, Italy; 3 Unit of COVID-19 Medicine, Department of Medicine, ASL1 Avezzano-Sulmona-L’Aquila, L’Aquila, Italy
Primary Sjögren’s Syndrome (pSS) is a systemic autoimmune disease characterized by a chronic inflammatory process mainly affecting the exocrine glands but also burdened by a wide range of extraglandular manifestations. Non-Hodgkin lymphoma (NHL) is the most severe pSS complication worsening disease prognosis. We summarized original articles published between April 2018 and May 2020 on this topic aiming to highlight novelties on lymphoma and lymphomagenesis. Results have been grouped by epidemiology, etiopathogenesis and predictors of lymphoma. NHL is the most severe complication of pSS and occurs in around 5-10% of patients. Over the last two years, several clinical, serological, and histopathological features have been proposed as predictive for lymphoma in pSS patients, allowing early diagnosis and consequently, better management and prognosis. Individual monitoring for disease activity and possible lymphoma development is a central clue in the evaluation of pSS patients.
KEY WORDS: Sjögren’s Syndrome; Lymphoma, non-Hodgkin; Lymphoma, B-cell, marginal zone; B-lymphocytes